Empagliflozin directly improves diastolic function in human heart failure

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 19,618 · see citing works

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866 · see citing works

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2016) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 662 · see citing works

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608 · see citing works

Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction

Franssen, C., Chen, H. S., Unger, A., Korkmaz, H. I., Keulenaer, G. W. D., Tschöpe, C., Leite-Moreira, A. F., Musters, R. J. P., Niessen, H. W. M., Linke, W. A., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.10.007 · Cited by 601 · see citing works

Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction

Westermann, D., Kašner, M., Paul Steendijk, A., Spillmann, F., Riad, A., Weitmann, K., Hoffmann, W. U., Poller, W. C., Pauschinger, M., Schultheiss, H., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.716886 · Cited by 471 · see citing works

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure

Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459 · see citing works

Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium

Borbély, A., Falcão‐Pires, I., van Heerebeek, L., Hamdani, N., Edes, I. F., Gavina, C., Leite-Moreira, A. F., Bronzwaer, J. G. F., Papp, Z., van der Velden, J., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.193326 · Cited by 360 · see citing works

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Sattar, N. A., McLaren, J. B., Kristensen, S. L., Preiss, D., & McMurray, J. J. V. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 310 · see citing works

Prevalence of Unrecognized Heart Failure in Older Persons with Shortness of Breath on Exertion

van Riet, E. E. S., Hoes, A. W., Limburg, A., Landman, M. A. J., van der Hoeven, H., & Rutten, F. H. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.110 · Cited by 304 · see citing works

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Steven, S., Oelze, M. W., Hanf, A., Kröller‐Schön, S., Kashani, F., Roohani, S., Welschof, P., Kopp, M., Gödtel‐Armbrust, U., Xia, N., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.009 · Cited by 299 · see citing works

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Barron, B. J., Mayoux, E., Rector, R. S., Whaley‐Connell, A. T., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0489-z · Cited by 264 · see citing works

Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts — Role of late sodium current and intracellular ion accumulation

Sossalla, S. T., Wagner, S., Rasenack, E. C. L., Ruff, H. M., Weber, S. L., Schöndube, F. A., Tirilomis, T., Tenderich, G., Hasenfuss, G. P., Belardinelli, L., et al. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.03.006 · Cited by 261 · see citing works

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0126-x · Cited by 237 · see citing works

Inhibition of Elevated Ca²⁺/Calmodulin-Dependent Protein Kinase II Improves Contractility in Human Failing Myocardium

Sossalla, S., Fluschnik, N., Schotola, H., Ort, K. R., Neef, S., Schulte, T., Wittköpper, K., Renner, A., Schmitto, J. D., Gummert, J., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.220418 · Cited by 237 · see citing works

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

Verma, S., Garg, A., Yan, A. T.-K., Gupta, A. K., Al-Omran, M. A., Sabongui, A., Teoh, H., Mazer, C. D., & Connelly, K. A. (2016) · Diabetes Care · doi:10.2337/dc16-1312 · Cited by 233 · see citing works

Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction

Hamdani, N., Bishu, K. G., von Frieling-Salewsky, M., Redfield, M. M., & Linke, W. A. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs353 · Cited by 227 · see citing works

Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model

Baartscheer, A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00809-x · Cited by 203 · see citing works

Crucial Role for Ca 2+ /Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation

Hamdani, N., Krysiak, J., Kreußer, M. M., Neef, S., dos Remedios, C. G., Maier, L. S., Krüger, M., Backs, J., & Linke, W. A. (2013) · Circulation Research · doi:10.1161/circresaha.111.300105 · Cited by 186 · see citing works

Sarcomeric dysfunction in heart failure

Hamdani, N., Kooij, V., van Dijk, S. J., Merkus, D., Paulus, W. J., dos Remedios, C. G., Duncker, D. J., Stienen, G. J. M., & van der Velden, J. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm079 · Cited by 179 · see citing works

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

Marx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165 · see citing works

Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target

Franco, A. D., Cantini, G., Tani, A., Coppini, R., Zecchi‐Orlandini, S., Raimondi, L., Luconi, M., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.032 · Cited by 164 · see citing works

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim‐Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 159 · see citing works

Ca 2+ /Calmodulin-Dependent Protein Kinase II and Protein Kinase A Differentially Regulate Sarcoplasmic Reticulum Ca 2+ Leak in Human Cardiac Pathology

Fischer, T. H., Herting, J., Tirilomis, T., Renner, A., Neef, S., Toischer, K., Ellenberger, D., Förster, A., Schmitto, J. D., Gummert, J. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001746 · Cited by 150 · see citing works

Myosin Crossbridge Activation of Cardiac Thin Filaments

Moss, R. L., Razumova, M. V., & Fitzsimons, D. P. (2004) · Circulation Research · doi:10.1161/01.res.0000127125.61647.4f · Cited by 149 · see citing works

Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes

Hammoudi, N., Jeong, D., Singh, R., Farhat, A. M., Michel Komajda, N., Mayoux, E., Hajjar, R. J., & Lebeche, D. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6734-1 · Cited by 149 · see citing works

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Heise, T., SEMAN, L. J., Macha, S., Jones, P., Marquart, A., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0030-2 · Cited by 127 · see citing works

Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts

Kötter, S., Gout, L., von Frieling-Salewsky, M., Müller, A. E., Helling, S., Marcus, K., dos Remedios, C. G., Linke, W. A., & Krüger, M. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt144 · Cited by 125 · see citing works

Molecular and Cellular Basis for Diastolic Dysfunction

van Heerebeek, L., Franssen, C., Hamdani, N., Verheugt, F. W. A., Somsen, G. A., & Paulus, W. J. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0109-5 · Cited by 123 · see citing works

Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4

Hamdani, N., Hervent, A.-S., Vandekerckhove, L., Matheeussen, V., Demolder, M. J., Baerts, L., Meester, I. D., Linke, W. A., Paulus, W. J., & Keulenaer, G. W. D. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu223 · Cited by 77 · see citing works

Glucose-transporter–mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients

von Lewinski, D., Rainer, P. P., Gasser, R. N. A., Huber, M.-S., Khafaga, M., Wilhelm, B., Haas, T., Mächler, H., Roessl, U., & Pieske, B. M. (2010) · Metabolism · doi:10.1016/j.metabol.2009.10.025 · Cited by 59 · see citing works

Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59 · see citing works

Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction

Hamdani, N., Paulus, W. J., van Heerebeek, L., Borbély, A., Boontje, N. M., Zuidwijk, M. J., Bronzwaer, J. G. F., Simonides, W. S., Niessen, H. W. M., Stienen, G. J. M., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp189 · Cited by 57 · see citing works

Diastolic myofilament dysfunction in the failing human heart

van der Velden, J. (2011) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-011-0960-3 · Cited by 49 · see citing works

Cardiovascular disease progression in female Zucker Diabetic Fatty rats occurs via unique mechanisms compared to males

Lum‐Naihe, K., Toedebusch, R. G., Mahmood, A., Bajwa, J., Carmack, T. L., Kumar, S., Ardhanari, S., DeMarco, V. G., Emter, C. A., & Pulakat, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-18003-8 · Cited by 43 · see citing works

Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) Inhibitor, in Mice, Rats, and Dogs

Chen, L., Mao, Y., Sharp, D. E., Schadt, S., Pagels, S., Press, R. J., Cheng, T., Mj, P., & Collins, W. (2015) · Journal of Pharmaceutics and Drug Development · doi:10.15744/2348-9782.3.302 · Cited by 10 · see citing works

4881Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

Zinman, B., Mathieu, C., Kaspers, S., Mattheus, M., Woerle, H. J., & FITCHETT, D. H. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx493.4881 · Cited by 2 · see citing works

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Zelniker, T. A., & D, E. B. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 586 · see citing works

From Systemic Inflammation to Myocardial Fibrosis

Paulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 396 · see citing works

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

Quagliariello, V., Laurentiis, M. D., Rea, D., Barbieri, A., Monti, M. G., Carbone, A., Paccone, A., Altucci, L., Conte, M., Canale, M. L., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01346-y · Cited by 371 · see citing works

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation

Kolijn, D., Pabel, S., Tian, Y., Lódi, M., Herwig, M., Carrizzo, A., Zhazykbayeva, S., Kovács, Á., Fülöp, G. Á., Falcão-Pires, I., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa123 · Cited by 323 · see citing works

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure

Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D. Y., Parajuli, N., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006277 · Cited by 260 · see citing works

Highlights in Heart Failure

Tomasoni, D., Adamo, M., Lombardi, C., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12555 · Cited by 259 · see citing works

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., di Martino, A. D., Albanese, G., Salvo, J. D., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 245 · see citing works

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

Lee, H., Shiou, Y.-L., Jhuo, S., Chang, C.-Y., Liu, P., Jhuang, W.-J., Dai, Z., Chen, W., Chen, Y.-F., & Lee, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0849-6 · Cited by 205 · see citing works

Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin

Juni, R. P., Kuster, D. W. D., Goebel, M., Helmes, M., Musters, R. J. P., van der Velden, J., Koolwijk, P., Paulus, W. J., & van Hinsbergh, V. W. M. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.003 · Cited by 204 · see citing works

Empagliflozin protects heart from inflammation and energy depletion via AMPK activation

Koyani, C. N., Plastira, I., Sourij, H., Hallström, S., Schmidt, A. G., Rainer, P. P., Bugger, H., Frank, S., Malle, E., & von Lewinski, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104870 · Cited by 194 · see citing works

European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure

Seferovic, P. M., Coats, A. J. S., Ponikowski, P. P., Filippatos, G. S., Huelsmann, M., Jhund, P. S., Polovina, M. M., Michel Komajda, N., Seferović, J. P., Sarı, İ., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 180 · see citing works

Direct cardiac effects of SGLT2 inhibitors

Chen, S., Coronel, R., Hollmann, M. W., Weber, N. C., & Zuurbier, C. J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01480-1 · Cited by 177 · see citing works

Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects

Dyck, J. R. B., Sossalla, S. T., Hamdani, N., Coronel, R., Weber, N. C., Light, P. E., & Zuurbier, C. J. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.03.005 · Cited by 177 · see citing works

Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy

Fumagalli, C., Maurizi, N., Day, S. M., Ashley, E. A., Michels, M., Colan, S. D., Jacoby, D. L., Marchionni, N., Vincent-Tompkins, J., Ho, C. Y., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4268 · Cited by 163 · see citing works

Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology

Seferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 132 · see citing works

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Cappetta, D., Angelis, A. D., Ciuffreda, L. P., Coppini, R., Cozzolino, A., Miccichè, A., Dell’Aversana, C., D’Amario, D., Cianflone, E., Scavone, C., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104781 · Cited by 127 · see citing works

SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?

Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 137 · see citing works

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Bosch, A., Ott, C., Jung, S., Striepe, K., Karg, M. V., Kannenkeril, D., Dienemann, T., & Schmieder, R. E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0839-8 · Cited by 125 · see citing works

Empagliflozin Inhibits Na+/H+ Exchanger Activity in Human Atrial Cardiomyocytes

Trum, M., Riechel, J., Lebek, S., Pabel, S., Sossalla, S. T., Hirt, S. W., Arzt, M. E., Maier, L. S., & Wagner, S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13024 · Cited by 115 · see citing works

Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction

Pandey, A. K., Bhatt, D. L., Pandey, A. K., Marx, N., Cosentino, F., Pandey, A., & Verma, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad389 · Cited by 119 · see citing works

Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association

Bogle, C., Colan, S. D., Miyamoto, S. D., Choudhry, S., Hernandez, N. B., Brickler, M. M., Feingold, B., Lal, A. K., Lee, T. M., Canter, C. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001151 · Cited by 111 · see citing works

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms

Huang, K., Luo, X., Liao, B., Li, G., & Feng, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01816-5 · Cited by 112 · see citing works

Doxorubicin-induced cardiotoxicity and risk factors

Belger, C., Abrahams, C., Imamdin, A., & Lecour, S. (2023) · International Journal of Cardiology: Heart & Vasculature · doi:10.1016/j.ijcha.2023.101332 · Cited by 113 · see citing works

Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future

Wintrich, J., Kindermann, I., Ukena, C., Selejan, S., Werner, C. M., Maack, C., Laufs, U., Tschöpe, C., Anker, S. D., Lam, C. S. P., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01633-w · Cited by 106 · see citing works

Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction

Omar, M., Jensen, J., Frederiksen, P. H., Kistorp, C., Videbæk, L. M., Poulsen, M. K., Möller, S., Ali, M., Gustafsson, F., Køber, L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.005 · Cited by 106 · see citing works

Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations

Law, J. P., Pickup, L. C., Pavlović, D., Townend, J., & Ferro, C. J. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00751-4 · Cited by 105 · see citing works

SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models

Andreadou, I., Bell, R. M., Bøtker, H. E., & Zuurbier, C. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165770 · Cited by 96 · see citing works

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Left Ventricular Function: Current Evidence and Future Directions

Lan, N. S. R., Fegan, P. G., Yeap, B. B., & Dwivedi, G. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12505 · Cited by 95 · see citing works

Effects of Atrial Fibrillation on the Human Ventricle

Pabel, S., Knierim, M., Stehle, T., Alebrand, F., Paulus, M., Sieme, M., Herwig, M., Barsch, F., Körtl, T., Pöppl, A., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319718 · Cited by 89 · see citing works

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

Sezai, A., Sekino, H., Unosawa, S., Taoka, M., Osaka, S., & Tanaka, M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0877-2 · Cited by 88 · see citing works

The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases

Zhazykbayeva, S., Pabel, S., Mügge, A., Sossalla, S. T., & Hamdani, N. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00742-0 · Cited by 83 · see citing works

Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

Kasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 79 · see citing works

HMGB1‐Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice

Zhang, X., Wang, T., Chen, Z., Wang, H., Yin, Y., Wang, L., Wang, Y., Xu, B., & Xu, W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023800 · Cited by 77 · see citing works

Heart Failure in the Last Year: Progress and Perspective

Tomasoni, D., Adamo, M., Anker, M. S., von Haehling, S., Coats, A. J. S., & Metra, M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13124 · Cited by 80 · see citing works

Heart failure with preserved ejection fraction based on aging and comorbidities

Lin, Y. H., Fu, S., Yao, Y., Li, Y., Zhao, Y., & Luo, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02935-x · Cited by 78 · see citing works

Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?

Cornuault, L., Rouault, P., Duplàa, C., Couffinhal, T., & Renault, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.906272 · Cited by 72 · see citing works

Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial

Tripolt, N. J., Kolesnik, E., Pferschy, P. N., Verheyen, N., Ablasser, K., Sailer, S., Alber, H. F., Berger, R., Kaulfersch, C., Leitner, K., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.12.004 · Cited by 68 · see citing works

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?

Trum, M., Riechel, J., & Wagner, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157976 · Cited by 68 · see citing works

Pathophysiological insights into HFpEF from studies of human cardiac tissue

Fayyaz, A. U., Eltony, M., Prokop, L. J., Koepp, K. E., Borlaug, B. A., Dasari, S., Bois, M. C., Margulies, K. B., Maleszewski, J. J., Wang, Y., et al. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01067-1 · Cited by 71 · see citing works

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction

Connelly, K. A., Zhang, Y., Desjardins, J., Nghiem, L., Visram, A., Batchu, S. N., Yerra, V. G., Kabir, G., Thai, K., Advani, A., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0994-y · Cited by 67 · see citing works

The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies

Cai, Z., Wu, C., Xu, Y., Cai, J., Zhao, M., & Zu, L. (2022) · Aging and Disease · doi:10.14336/ad.2022.0523 · Cited by 67 · see citing works

Empagliflozin improves left ventricular diastolic function of db/db mice

Moellmann, J., Klinkhammer, B. M., Droste, P., Kappel, B. A., Haj‐Yehia, E., Maxeiner, S., Artati, A., Adamski, J., Boor, P., Schütt, K. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165807 · Cited by 63 · see citing works

Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function

Ciccarelli, M., Dawson, D. K., Falcão‐Pires, I., Giacca, M., Hamdani, N., Heymans, S. R. B., Hooghiemstra, A. M., Leeuwis, A. E., Hermkens, D. M. A., Tocchetti, C. G., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab009 · Cited by 61 · see citing works

Redox signaling in heart failure and therapeutic implications

Weissman, D., & Maack, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.013 · Cited by 59 · see citing works

Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients

Starčević, J. N., Janić, M., & Šabović, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051197 · Cited by 58 · see citing works

Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value

Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 58 · see citing works

Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a

Goerg, J., Sommerfeld, M., Greiner, B., Lauer, D., Seckin, Y., Kulikov, A. N., Ivkin, D. Y., Kintscher, U., Okovityi, S. V., & Kaschina, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115437 · Cited by 53 · see citing works

Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype

Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51 · see citing works

Repurposing Antidiabetic Drugs for Cardiovascular Disease

Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 51 · see citing works

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction

Budde, H., Hassoun, R., Mügge, A., Kov́acs, Á., & Hamdani, N. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.928232 · Cited by 53 · see citing works

Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors

Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 52 · see citing works

Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis

Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01209-y · Cited by 47 · see citing works

Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities

Yi, M., Cisneros, L., Cho, E. J., Alexander, M., Kimelman, F. A., Swentek, L., Ferrey, A., Tantisattamo, E., & Ichii, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020821 · Cited by 46 · see citing works

Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors

Wijnker, P. J. M., Dinani, R., van der Laan, N. C., Algül, S., Knollmann, B. C., Verkerk, A. O., Remme, C. A., Zuurbier, C. J., Kuster, D. W. D., & van der Velden, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae004 · Cited by 45 · see citing works

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction

Peng, X., Li, L., Zhang, M., Zhao, Q., Wu, K., Bai, R., Ruan, Y., & Liu, N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00912 · Cited by 45 · see citing works

Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain

Schauer, A., Adams, V., Kämmerer, S., Langner, E., Augstein, A., Barthel, P., Männel, A., Fabig, G., Alves, P. K. N., Günscht, M., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011107 · Cited by 44 · see citing works

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis

Chung, C., Lin, Y., Chen, Y., Kao, Y., Yeh, Y., Trang, N. N., & Chen, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01756-0 · Cited by 43 · see citing works

Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study

Akasaka, H., Sugimoto, K., Shintani, A., Taniuchi, S., Yamamoto, K. I., Iwakura, K., Okamura, A., Takiuchi, S., Fukuda, M., Kamide, K., et al. (2022) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14363 · Cited by 42 · see citing works

Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial

Paiman, E. H. M., van Eyk, H. J., van Aalst, M., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 42 · see citing works

Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy

Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 40 · see citing works

Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension

Gu, J., Yin, Z., Zhang, J., & Wang, C. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.11.087 · Cited by 36 · see citing works

Reappraisal on pharmacological and mechanical treatments of heart failure

Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 37 · see citing works

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

Pabel, S., Hamdani, N., Singh, J. S., & Sossalla, S. T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.752370 · Cited by 35 · see citing works

Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2

Bruckert, C., Matsushita, K., Mroueh, A., Amissi, S., Auger, C., Hounguè, U., Remila, L., Chaker, A. B., Park, S., Algara‐Suárez, P., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107095 · Cited by 34 · see citing works

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Karakasis, P., Fragakis, N., Κούσκουρας, Κ., Karamitsos, T. D., Patoulias, D., & Rizzo, M. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.010 · Cited by 34 · see citing works

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients

Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35 · see citing works

Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions

Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32 · see citing works

Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Kashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 32 · see citing works

The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy

Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 32 · see citing works

Sodium-induced inflammation—an invisible player in resistant hypertension

Targoński, R., Sadowski, J., Price, S., & Targoński, R. (2020) · Hypertension Research · doi:10.1038/s41440-020-0428-y · Cited by 31 · see citing works

Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review

Panico, C., Bonora, B. M., Camera, A., Chilelli, N. C., Prato, G. D., Favacchio, G., Grancini, V., Resi, V., Rondinelli, M., Zarra, E., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01855-y · Cited by 33 · see citing works

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research

Chen, L., Ma, S., Hu, D., Lin, H., Zhu, Y., Chen, K., Chen, L., Zheng, C., Liu, J., & Liao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561494 · Cited by 29 · see citing works

Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review

Matsumura, K., & Sugiura, T. (2019) · Cardiovascular Ultrasound · doi:10.1186/s12947-019-0177-8 · Cited by 28 · see citing works

Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events

Sarzani, R., Giulietti, F., Pentima, C. D., & Spannella, F. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.030 · Cited by 29 · see citing works

Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets

Severino, P., D’Amato, A., Prosperi, S., Fanisio, F., Birtolo, L. I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., Maestrini, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147650 · Cited by 28 · see citing works

The Interplay between S-Glutathionylation and Phosphorylation of Cardiac Troponin I and Myosin Binding Protein C in End-Stage Human Failing Hearts

Budde, H., Hassoun, R., Tangos, M., Zhazykbayeva, S., Herwig, M., Varatnitskaya, M., Sieme, M., Delalat, S., Sultana, I., Kolijn, D., et al. (2021) · Antioxidants · doi:10.3390/antiox10071134 · Cited by 27 · see citing works

CaMKII and GLUT1 in heart failure and the role of gliflozins

Trum, M., Wagner, S., Maier, L. S., & Mustroph, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165729 · Cited by 27 · see citing works

Cardioprotective effects of short-term empagliflozin treatment in db/db mice

Radlinger, B., Hornsteiner, F., Folie, S., Salvenmoser, W., Haubner, B. J., Schuetz, T., Haas, S., Ress, C., Adolph, T. E., Salzmann, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76698-8 · Cited by 26 · see citing works

Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

Siddiqui, R., Obi, Y., Dossabhoy, N. R., & Shafi, T. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01314-3 · Cited by 25 · see citing works

Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes

Pabel, S., Reetz, F., Dybkova, N., Shomroni, O., Salinas, G., Mustroph, J., Hammer, K. P., Hasenfuss, G. P., Hamdani, N., Maier, L. S., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01989-6 · Cited by 24 · see citing works

Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial

Prochaska, J. H., Jünger, C., Schulz, A., Arnold, N., Müller, F., Heidorn, M. W., Baumkötter, R., Zahn, D., Koeck, T., Tröbs, S., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02164-w · Cited by 24 · see citing works

Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus

Shi, Y., Dong, G., & Guo, M. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.724 · Cited by 24 · see citing works

What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?

Daou, D., Tong, D., Schiattarella, G. G., Gillette, T. G., & Hill, J. A. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.009 · Cited by 27 · see citing works

Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model

Baka, T., Moore, J., Qin, F., Yurista, S. R., Zhang, A., He, H., Chambers, J. M., Croteau, D., Goel, R. K., Smith, H. R., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf324 · Cited by 22 · see citing works

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?

Voorrips, S. N., Saucedo‐Orozco, H., Sánchez-Aguilera, P., de Boer, R. A., van der Meer, P., & Westenbrink, B. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158631 · Cited by 24 · see citing works

Stratified Treatment of Heart Failure with Preserved Ejection Fraction: Rationale and Design of the STADIA-HFPEF Trial

Scheffer, M., Driessen‐Waaijer, A., Hamdani, N., Landzaat, J. W. D., Jonkman, N. H., Paulus, W. J., & van Heerebeek, L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13055 · Cited by 21 · see citing works

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats

He, L., Ma, S., Zuo, Q., Zhang, G., Wang, Z., Zhang, T., Zhai, J., & Guo, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856386 · Cited by 21 · see citing works

Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na+/H+ exchanger-1

Baker, H. E., Tune, J. D., Mather, K. J., Blaettner, B. S., Clark, H. E., Li, F., Li, X., Kowala, M. C., Fliegel, L., & Goodwill, A. G. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.054 · Cited by 21 · see citing works

Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium

Amesz, J. H., Langmuur, S. J. J., Epskamp, N., Bogers, A. J. J. C., de Groot, N. M. S., Manintveld, O. C., & Taverne, Y. J. H. J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07434-3 · Cited by 20 · see citing works

Regression of left ventricular hypertrophy with SGLT2 inhibitors

Paneni, F., Costantino, S., & Hamdani, N. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa530 · Cited by 20 · see citing works

Right-Ventricular Dysfunction in HFpEF is Linked to Altered Cardiomyocyte Ca2+ Homeostasis and Myofilament Sensitivity

Hegemann, N., Primeßnig, U., Bode, D., Wakula, P., Beindorff, N., Klopfleisch, R., Michalick, L., Grune, J., Hohendanner, F., Messroghli, D., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13419 · Cited by 19 · see citing works

SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoring

Kirschbaum, K., Vasa‐Nicotera, M., Zeiher, A. M., & Cremer, S. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01954-4 · Cited by 19 · see citing works

Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus–A randomized, placebo-controlled cross-over study

Suhrs, H. E., Nilsson, M., Bove, K. B., Zander, M., & Prescott, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263481 · Cited by 19 · see citing works

Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1

dos Santos, D. S., Turaça, L. T., Coutinho, K. C. D. S., Barbosa, R. A. Q., Polidoro, J. Z., Kasai-Brunswick, T. H., de Carvalho, A. C. C., & Girardi, A. C. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-35944-5 · Cited by 19 · see citing works

Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial

Ovchinnikov, A. G., Potekhina, A. V., Filatova, A. Y., Николаевна, С. О., Zherebchikova, K., Ageev, F. T., & Belyavskiy, E. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02756-y · Cited by 18 · see citing works

Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner

Peng, X., Li, L., Lin, R., Wang, X., Liu, X., Li, Y., Ma, C., Ruan, Y., & Liu, N. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07311-x · Cited by 18 · see citing works

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors

Heath, R., Johnsen, H. S., Strain, W. D., & Evans, M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01204-4 · Cited by 19 · see citing works

Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features

Herwig, M., Sieme, M., Kovács, A., Khan, M., Mügge, A., Schmidt, W. E., Elci, F., Sasidharan, S., Haldenwang, P. L., Wintrich, J., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02748-y · Cited by 19 · see citing works

SGLT2 inhibitors in heart failure with reduced ejection fraction

Das, U. S., Paul, A., & Banerjee, S. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00218-w · Cited by 17 · see citing works

Empagliflozin—A New Chance for Patients with Chronic Heart Failure

Kowalska, K., Walczak, J., Femlak, J., Młynarska, E., Franczyk, B., & Rysz, J. (2021) · Pharmaceuticals · doi:10.3390/ph15010047 · Cited by 17 · see citing works

P1509Empagliflozin directly improves diastolic function in human heart failure

Pabel, S., Bollenberg, H., Bengel, P., Tirilomis, P., Mustroph, J., Wagner, S., Fischer, T. H., Streckfuß‐Bömeke, K., Maier, L. S., Hasenfuss, G. P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy565.p1509 · Cited by 6 · see citing works

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure

Santos‐Gallego, C. G., Requena-Ibáñez, J. A., Antonio, R. S., García‐Ropero, Á., Ishikawa, K., Watanabe, S., Picatoste, B., Vargas-Delgado, A. P., Flores‐Umanzor, E., Sanz, J., et al. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.07.042 · Cited by 196 · see citing works

Pleiotrope Effekte Empagliflozins auf humanes und murines Myokard

Bollenberg, H. (2025) · doi:10.53846/goediss-11372

A mechanistic rationale for the investigation of sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article ‘Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial’

Pabel, S., Hamdani, N., & Sossalla, S. T. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2091 · Cited by 6 · see citing works

EFFECTS OF LOW-DOSE EMPAGLIFLOZIN TREATMENT ON DIASTOLIC HEART FUNCTION IN INFARCTED DIABETIC RATS

da Silva, B. D., de Souza, L. E., da Silva, M. B., Cruz, P. L., Dourado, P. M. M., Consolim‐Colombo, F. M., & Irigoyen, M. C. (2020) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(20)31671-5